Financial Data and Key Metrics Changes - In fiscal 2022, the company reported net sales of $284 million, with a negative impact of $12.9 million from changes in constant currency [7][70] - For Q4 2022, total net sales were $64 million, a 5 million year-over-year increase from $59 million in Q4 2021, driven by a 15% increase in ICL sales [70] - Operating income for fiscal 2022 was $43.8 million, representing 15.4% of net sales, compared to $33.3 million or 14.5% of net sales for fiscal 2021 [83] - Gross profit for Q4 2022 was $49.8 million, or 77.7% of net sales, compared to 76.3% in Q4 2021 [82] Business Line Data and Key Metrics Changes - ICL sales grew 27% year-over-year, with ICL units increasing by 33% [4] - In Q4 2022, ICL unit growth was up 20% year-over-year, with significant growth in the U.S. at 109% [80][105] - The company plans to discontinue its non-core lower-margin cataract IOL business after 2023 [70] Market Data and Key Metrics Changes - In China, ICL unit growth was 18% in Q4 2022, with Japan at 33% and India at 19% [80] - U.S. sales in Q4 2022 were approximately $4.5 million, reflecting a 94% year-over-year increase [107] - Doctor Finder visits in the U.S. increased by approximately 600% year-over-year in Q4 [81] Company Strategy and Development Direction - The company aims to leverage its financial strength to build the U.S. market, focusing on increasing consumer awareness and surgeon confidence in EVO adoption [6] - Plans for 2023 include doubling spending on EVO digital marketing campaigns and increasing sales and clinical personnel [6] - The company is committed to surrounding U.S. surgeons with clinical and sales support to integrate EVO into their practices [105] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the recovery of the China market, noting that refractive procedures are returning to normal levels [10][68] - The company anticipates a weighted sales calendar in 2023, with expectations for Q1 net sales to be between $65 million and $67 million [7] - Management remains optimistic about the U.S. market potential, citing strong commitments from larger customers and increased surgeon engagement [32][68] Other Important Information - The company generated $35.7 million in cash from operations in fiscal 2022 and ended the year with over $225 million in cash and investments [35] - For fiscal 2023, the company expects R&D expenses to be approximately $11 million each quarter, focusing on post-approval studies and quality [8][103] Q&A Session Summary Question: What is the outlook for the China market? - Management expressed confidence in the China market, noting no travel restrictions and a return to normal refractive procedures [10] Question: Can you elaborate on the U.S. EVO launch and practice development efforts? - The company is increasing its infrastructure and support for U.S. surgeons to enhance EVO adoption [22][105] Question: How significant was the backlog of procedures in China due to COVID? - Management indicated that the backlog is being addressed, with confidence in meeting projections for the year [15][43] Question: What are the expectations regarding FDA proposals for LASIK patient disclaimers? - Management stated that they cannot predict the timing of FDA decisions but emphasized that EVO's clinical trial data has already been approved [44] Question: How is the company addressing price competition in the U.S.? - Management clarified that price is not a factor in their growth strategy and they do not plan to use promotions to spur demand [28][102]

Financial Data and Key Metrics Changes - Total net sales for Q3 2022 were $76 million, up 30% compared to $58.4 million in Q3 2021, with a 33% increase in ICL sales, representing 95% of total net sales [20][28] - Gross profit was $60.5 million or 79.5% of net sales, compared to 77.6% in Q3 2021, reflecting a 190 basis point year-over-year increase [23] - Operating income was $13.7 million or 18% of net sales, compared to $7.8 million or 13.4% in Q3 2021 [27] Business Line Data and Key Metrics Changes - Global ICL unit growth was up 40% year-over-year, with significant growth in the U.S. (63%), China (52%), Japan (40%), and South Korea (49%) [9][13] - ICL sales are anticipated to be approximately $272 million for fiscal 2022, representing 28% year-over-year growth [10] Market Data and Key Metrics Changes - In China, the company expects to exceed a 25% share of the refractive surgery market units by year-end, despite COVID-related delays [10] - The U.S. market is projected to see unit growth accelerate to approximately 100% year-over-year in Q4 2022 [18] Company Strategy and Development Direction - The company is focusing on the growth opportunities with its premium EVO products while phasing out its low-margin other products business [11][19] - STAAR aims to achieve approximately 30% ICL sales growth year-over-year to approximately $355 million in total company net sales for fiscal 2023 [12][32] Management's Comments on Operating Environment and Future Outlook - Management highlighted challenges such as tighter COVID restrictions in China and macroeconomic headwinds in Europe but remains optimistic about growth in the U.S. and Asia [10][12] - The company anticipates a strong trajectory of growth for EVO ICL and continued market share gains in 2023 [19][32] Other Important Information - The company has trained over 550 U.S. surgeons on EVO lenses and expects to exceed its goal of training 600 by the end of 2022 [16][18] - STAAR has implemented an investment policy to maximize returns on cash, resulting in a cash balance of $224.7 million as of September 30, 2022 [29][30] Q&A Session Summary Question: What are the headwinds affecting the Q4 implied outlook? - Management identified approximately $5 million in delayed revenue due to COVID lockdowns in China, $2 million from European macroeconomic factors, and $1.5 million from foreign exchange impacts [38] Question: What is the expected growth in China for 2023? - Management expects unit growth in China to exceed 30% in 2023, despite lingering COVID headwinds [41] Question: How is the U.S. market performing? - The U.S. market is expected to see strong growth, with management projecting significant market share gains within 18 months [42] Question: What is the impact of the phase-out of other products on ICL use? - Management does not anticipate a negative impact on ICL use due to the phase-out of other products, as they will continue to support customers during the transition [57] Question: How does the company expect to achieve the $355 million target for 2023? - The target includes a mix of unit growth and pricing, with expectations for a healthy average selling price in the U.S. [72]

Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Registrant as Specified in its Charter) (Registrant's Telephone Number, Including Area Code) Securities registered ...

Financial Data and Key Metrics Changes - Total net sales for Q2 2022 were $81.1 million, representing a 30% year-over-year increase from $62.4 million in Q2 2021 and a 28% increase sequentially from Q1 2022 [29] - ICL sales accounted for 96% of total company net sales, similar to the previous year [30] - Gross profit for Q2 2022 was $63.9 million, or 78.8% of net sales, compared to 78.9% in Q2 2021 [33] - Net income for Q2 2022 was $13 million, or $0.26 per diluted share, compared to $8.6 million, or $0.17 per diluted share in Q2 2021 [41] Business Line Data and Key Metrics Changes - Global ICL unit growth was up 42% year-over-year, with significant growth in various regions: China (up 45%), the U.S. (up 36%), Japan (up 41%), India (up 181%), and Asia Pacific distributor markets (up 66%) [15] - The company reaffirmed its fiscal 2022 net sales outlook of approximately $295 million, despite currency headwinds [26] Market Data and Key Metrics Changes - The U.S. market showed strong adoption of the EVO family of lenses, with over 400 surgeons trained and certified, aiming for at least 600 by year-end [22] - In China, the company reported a strong busy season for EVO procedures, with effective management of COVID-19 related challenges [17] Company Strategy and Development Direction - The company is focusing on expanding its EVO lens offerings and enhancing brand awareness through partnerships with influencers, such as Joe Jonas [12][20] - Plans to showcase the EVO family of lenses at major industry events, including the European Society of Cataract and Refractive Surgeons Congress [24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about navigating current COVID-19 challenges and meeting anticipated demand levels [17] - The company expects to continue seeing robust ICL unit growth and has adjusted its outlook for the second half of the year to account for currency impacts [32] Other Important Information - The company received its five-year MDR Certification from the European Notified Body, DEKRA, highlighting its commitment to quality [13] - The company plans to participate in several investor conferences and events in the coming weeks [45] Q&A Session Summary Question: Impact of influencer partnerships on sales trajectory - Management indicated that launching with a major influencer typically results in increased interest and a significant bump in sales, with expectations for a strong campaign rollout in the U.S. [48] Question: Long-term market share growth in China - Management confirmed a commitment to expanding distribution and partnerships in China, with a focus on both large and smaller clinics [50] Question: U.S. revenue impacts from inventory reserves - Management clarified that the reserve taken on the old Visian product did not impact revenue but was reflected in the cost of goods [56] Question: Surgeons' training and adoption rates - Management noted that the training of surgeons is progressing well, with expectations for continued growth in adoption rates for EVO lenses [82] Question: Pricing and ASPs in different markets - Management acknowledged that ASPs are expected to increase as the U.S. market grows, despite lower ASPs in China due to competitive pricing [75] Question: Gross margin expectations amid inflation - Management indicated that operational efficiencies are helping to maintain gross margins despite inflationary pressures [89]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: July 1, 2022 Or (626) 303-7902 (Registrant's Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlantic Ocean Drive STAAR SURGICAL COMPANY Lake Forest, California 92630 ☐ TRANSITI ...

STAAR Surgical Company (NASDAQ:STAA) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Brian Moore - Vice President, Investor, Media Relations and Corporate Development Caren Mason - President and Chief Executive Officer Patrick Williams - Chief Financial Officer Conference Call Participants Bill Plovanic - Canaccord Zach Weiner - Jefferies Ryan Zimmerman - BTIG Chris Cooley - Stephens Andrew Brackmann - William Blair David Saxon - Needham Disclaimer*: This transcript is designed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: April 1, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) 25651 Atlantic O ...

Financial Data and Key Metrics Changes - Total net sales for Q4 2021 were $59 million, up 28% compared to $46 million in Q4 2020 and up 1% sequentially from Q3 2021 [19] - Gross profit for Q4 2021 was $45 million, or 76.3% of net sales, compared to $34.3 million, or 74.6% of net sales in Q4 2020 [22] - Net income in Q4 2021 was $4.9 million, or $0.10 per diluted share, compared to $3.3 million, or $0.07 per diluted share in Q4 2020 [29] Business Line Data and Key Metrics Changes - ICL sales represented 90% of total company net sales for Q4 2021, up from 87% in the prior year quarter [21] - ICL unit growth for fiscal 2021 was up 48% year-over-year, significantly outpacing the 17% increase in global industry refractive procedures [10] Market Data and Key Metrics Changes - ICL unit growth in various markets for Q4 2021 included China up 44%, Japan up 45%, South Korea up 35%, India up 74%, and Latin America up 30% compared to the prior year quarter [11] - The U.S. is estimated to have 100 million adults aged 21 to 45 who are potential candidates for implantable Collamer lenses [15] Company Strategy and Development Direction - The company plans to invest more heavily in consumer awareness programs to accelerate the shift to lens-based vision correction [15] - STAAR aims to triple its manufacturing capacity within the next 18 months to meet growing demand [57] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed the fiscal 2022 net sales outlook of approximately $295 million, representing 28% year-over-year growth [13] - The company expects to return to a more normal pre-pandemic sales calendarization in 2022, with approximately 48% of net sales in the first half of the year [20] Other Important Information - The company anticipates a gross margin of approximately 77% for Q1 and full year 2022, with investments in manufacturing facilities [23] - Capital expenditures for 2022 are expected to be approximately $20 million, primarily for manufacturing expansion [31][76] Q&A Session Summary Question: Update on discussions with the FDA - Management is in customary interactive review with the FDA and feels confident about a positive result for their submission [36] Question: Impact of the Olympics on branding opportunities in China - Management noted strong orders from surgeons in China and attributed growth to effective social media and digital marketing efforts [37] Question: Current backlog status and its impact on guidance - Management confirmed a healthy backlog and indicated that some of it is factored into the 2022 guidance, with strong current orders providing an opportunity to overperform [42] Question: Capacity and supply chain issues - Management is working to triple current capacity within 18 months and aims to have reserve inventory capability of 30% to 40% of projected demand [57] Question: Tax rate expectations for 2022 - The anticipated tax rate for 2022 is approximately 30%, influenced by the geographical mix of profitability [77] Question: Continuation of COVID impacts on guidance - Management has taken potential COVID-related headwinds into account but remains optimistic about a strong start to 2022 [82] Question: FDA requirements for manufacturing expansions - Management explained that some expansions require inspections while others may only need notification, depending on regulatory requirements [87]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact name of registrant as specified in its charter) Delaware 95-3797439 (Registrant's telephone number ...

Financial Data and Key Metrics Changes - Total net sales for Q3 2021 were $58.4 million, up 24% compared to $47.1 million in Q3 2020, exceeding the previous outlook of $57 million to $58 million [25][26] - Gross profit for Q3 2021 was $45.3 million, or 77.6% of net sales, compared to 74.1% in Q3 2020 [28] - Net income in Q3 2021 was $6 million, or $0.12 per diluted share, compared to $3.9 million, or $0.08 per share in Q3 2020 [35][36] Business Line Data and Key Metrics Changes - ICL sales represented 93% of total company net sales for Q3 2021, with other products accounting for 7% [27] - Global ICL sales growth was up 31% year-over-year, with expectations for Q4 to exceed 40% growth [26][24] Market Data and Key Metrics Changes - ICL unit growth by geography included: Japan up 44%, South Korea up 21%, India up 338%, Germany up 25%, European distributor markets up 22%, Middle East and North Africa up 242%, and the U.S. up 66% compared to the prior year quarter [16] - China remains the largest market, with distributor inventory levels drawn down to historically low levels to meet demand [11] Company Strategy and Development Direction - The company is raising its full-year fiscal 2021 net sales outlook to a range of $230 million to $231 million, representing over 40% year-over-year growth [24] - Strategic imperatives include increasing marketing investments in key U.S. cities and expanding engagement with surgeons [19][21] - The company plans to open an ICL Experience Center in California in the first half of 2022 to enhance surgeon training and marketing education [23] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in overcoming temporary supply chain challenges and anticipates catching up on backlog in Q4 and Q1 2022 [50][54] - The company remains optimistic about achieving a compound annual growth rate of over 25% from 2020 to 2022, despite the impact of COVID-19 [24][68] Other Important Information - Cash and cash equivalents as of October 1, 2021, totaled $196.2 million, up from $152.5 million at the end of Q4 2020 [37] - The company plans to participate in several upcoming investor events, including the Canaccord Genuity Virtual MedTech & Diagnostics Forum [38] Q&A Session Summary Question: Regarding the backlog of 20,000 lenses - Management confirmed that the majority of the backlog is related to China and estimated that it could represent at least $65 million in revenue for the quarter if shipped [42] Question: Timing for distributor restocking - Management indicated that replenishment of inventory in China is already underway and they are prepared for the next big season starting in January [45] Question: Supply chain issues and their impact - Management clarified that the supply chain issues were not exclusive to China but were managed effectively to meet critical demand [88] Question: Expectations for U.S. market penetration post-launch - Management aims to achieve at least 20% market share in the U.S. within two to three years post-approval [95] Question: Growth driven by refractive market versus conversions - Management stated that the refractive market grows in the mid-single digits, while the company is growing at least 25% plus, indicating market share gains [82]